Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer

November 30th 2017

Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.

Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

November 30th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

November 30th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

Immunotherapy Combo Regimens Next Step in Bladder Cancer

November 30th 2017

Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.

Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer

November 30th 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

Future of Bladder Cancer Care to Include Immunotherapy Combos

November 29th 2017

Petros Grivas, MD, shares insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.

Agarwal Recaps Advancements in Newly Diagnosed RCC

November 27th 2017

Neeraj Agarwal, MD, recaps the latest advancements in newly diagnosed RCC.

Dr. Holzbeierlein on the Management of Bladder Cancer Guidelines

November 23rd 2017

Jeffrey M. Holzbeierlein, MD, professor, director of Urologic Oncology, Department of Urology, University of Kansas Medical Center, discusses the management guidelines for patients with bladder cancer.

Dr. Jonasch on the CABOSUN Trial in RCC

November 22nd 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).

EU Approves Abiraterone for Newly Diagnosed Hormone-Sensitive Prostate Cancer

November 22nd 2017

The European Commission has approved abiraterone acetate (Zytiga) in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer.

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

November 21st 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Optimizing Adjuvant Therapy in Renal Cell Carcinoma

November 20th 2017

Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.

Immunotherapy Continues to Shape Future Bladder Cancer Paradigm

November 20th 2017

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer

November 19th 2017

Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

November 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Incentivizing the Lower-Cost Decision: LUGPA Believes It Knows How

November 19th 2017

A newly proposed urology-specific alternative payment model could save up to 37% on costs of care, partly by giving physicians incentives to pursue active surveillance rather than active intervention, according to the Large Urology Group Practice Association.

Next Steps in Bladder Cancer to Include Combination Immunotherapy

November 19th 2017

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC

November 18th 2017

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC Treatment

November 18th 2017

Kerstin Junker, MD, associate professor, Department of Urology, Universit

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

November 18th 2017

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.